Inhibikase Therapeutics Inc reports results for the quarter ended in March - Earnings Summary

Inhibikase Therapeutics

16/05/2024 03:50

* Inhibikase Therapeutics Inc  IKT.OQ  reported a quarterly
adjusted loss of 73 cents​​ per share for the quarter ended in
March, higher than the same quarter last year, when the company
reported EPS of -96 cents.  The lone analyst forecast for the
quarter was for a loss of 79 cents per share. 
    * Reported revenue was zero​; analysts expected zero. 
    * Inhibikase Therapeutics Inc's reported EPS for the quarter
was a
loss of 73 cents​.
    * The company reported a quarterly loss of $4.65 million.
    * Inhibikase Therapeutics Inc shares had fallen by 28.7%
this
quarter and gained 21.3% so far this year.

FORECAST CHANGES
    * The mean earnings estimate of analysts was unchanged in
the last
three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.

RECOMMENDATIONS
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 2 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 
    * The average consensus recommendation for the biotechnology
&
medical research peer group is also "buy"

Wall Street's median 12-month price target for Inhibikase
Therapeutics Inc is $17.50 
This summary was machine generated from LSEG data May 16 at
02:49 a.m. UTC. ​All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Mar. 31 2024      -0.79          -0.73          Beat
 Dec. 31 2023      -0.85          -0.64          Beat
 Sep. 30 2023      -1.12          -0.86          Beat
 Jun. 30 2023      -0.92          -1.11          Missed